Chinese prescription Kangen-karyu prevents dyslipidaemia and oxidative stress in mouse model of type 2 diabetes

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 1, 2011, Pages 111-119

  Noh, Jeong Sook ^a   Park, Chan Hum ^a   Kim, Hyun Young ^b   Zhao, Qi ^a   Yamabe, Noriko ^a   Matsumoto, Kinzo ^a   Yokozawa, Takako ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Gyeongsang National University   (South Korea)

Author keywords

db db mice; hyperlipidaemia; Kangen karyu; oxidative stress; type 2 diabetes

Indexed keywords

ANTILIPEMIC AGENT; CHINESE DRUG; CHOLESTEROL; CYCLOOXYGENASE 2; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; KANGEN KARYU; LIPID; LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPID PEROXIDATION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRESCRIPTION; PROTEIN EXPRESSION;

ANIMALS; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; DYSLIPIDEMIAS; LIPID METABOLISM; LIPID PEROXIDATION; LIVER; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; TRIGLYCERIDES;

EID: 78650411008     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01156.x     Document Type: Article

References (42)

1. Shimabukuro M, et al. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA 1998; 95: 2498-2502.
2. McGarry JD,. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51: 7-18.
3. Poitout V, Robertson RP,. Minireview: secondary beta-cell failure in type 2 diabetes-a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002; 143: 339-342.
4. Prentki M, et al. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes 2002; 51: S405-S413.
5. Takahashi M, et al. Kangenkaryu prevents the decrease of cholinergic markers following the nucleus basalis magnocellularis lesion. Jpn J Pharmacol 1992; 60: 307-310.
6. Gao M, et al. Studies on preventive effect of Kangen-karyu Chinese herbal medicine, on stroke in SHR-SP. J Trad Med 2001; 18: 245-250.
7. Makino T, et al. Effects of Kangen-karyu on coagulation system and platelet aggregation in mice. Biol Pharm Bull 2002; 25: 523-525.
8. 2-induced premature senescence. J Pharm Pharmacol 2008; 60: 1537-1544.
9. Yokozawa T, et al. The protective role of Chinese prescription Kangen-karyu extract on diet-induced hypercholesterolemia in rats. Biol Pharm Bull 2006; 29: 760-765.
10. Yokozawa T, et al. The protective effect role of Kangen-karyu against fructose-induced metabolic syndrome in a rat model. J Pharm Pharmacol 2007; 59: 1271-1278.
11. Kim HY, et al. Beneficial effects of Chinese prescription Kangen-karyu on diabetes associated with hyperlipidemia, advanced glycation endproducts, and oxidative stress in streptozotocin-induced diabetic rats. J Ethnopharmacol 2009; 124: 263-269.
12. Hummel KP, et al. Diabetes, a new mutation in the mouse. Science 1966; 153: 1127-1128.
13. Kaku K, et al. Genetic analysis of obesity-induced diabetes associated with a limited capacity to synthesize insulin in C57BL/KS mice: evidence for polygenic control. Diabetologia 1989; 32: 636-643.
14. Münzberg H, Myers MG Jr,. Molecular and anatomical determinants of central leptin resistance. Nat Neurosci 2005; 8: 566-570.
15. Orland MJ, Permutt MA,. Quantitative analysis of pancreatic proinsulin mRNA in genetically diabetic (db/db) mice. Diabetes 1987; 36: 341-347.
16. Ali SF, et al. Reactive oxygen species formation as a biomarker of methylmercury and trimethyltin neurotoxicity. Neurotoxicology 1992; 13: 637-648.
17. Naito C, Yamanaka T,. Atherosclerosis and peroxidative lipid. Jpn J Geriatr 1978; 15: 187-191.
18. Folch J, et al. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957; 226: 497-509.
19. Mihara M, Uchiyama M,. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 1978; 86: 271-278.
20. Park CW, et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 2007; 18: 1227-1238.
21. Scott JA, King GL,. Oxidative stress and antioxidant treatment in diabetes. Ann N Y Acad Sci 2004; 1031: 204-213.
22. Tushuizen ME, et al. Pancreatic fat content and β-cell function in men with and without type 2 diabetes. Diabetes Care 2007; 30: 2916-2921.
23. Evans JL, et al. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 2003; 52: 1-8.
24. Niki E, et al. Membrane damage due to lipid oxidation. Am J Clin Nutr 1991; 53: 201S-205S.
25. ob mice. J Biol Chem 2002; 277: 19353-19357.
26. Shimano H, et al. Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J Biol Chem 1999; 274: 35832-35839.
27. -/- mouse liver. J Biol Chem 2001; 276: 38337-38340.
28. db/db mice with type 2 diabetes. Diabetes 2005; 54: 2328-2335.
29. Ferré P,. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 2004; 53: S43-S50.
30. Brown MS, Goldstein JL,. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997; 89: 331-340.
31. Shimano H, et al. Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene. J Clin Invest 1997; 100: 2115-2124.
32. Shimomura I, et al. Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 1997; 99: 838-845.
33. Horton JD, et al. Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J Clin Invest 1998; 101: 2331-2339.
34. Shimomura I, et al. Nuclear sterol regulatory element-binding proteins activate genes responsible for the entire program of unsaturated fatty acid biosynthesis in transgenic mouse liver. J Biol Chem 1998; 273: 35299-35306.
35. Goldstein JL, Brown MS,. Regulation of the mevalonate pathway. Nature 1990; 343: 425-430.
36. Girard J, et al. Regulation of lipogenic enzyme gene expression by nutrients and hormones. FASEB J 1994; 8: 36-42.
37. Nestel P, Goldrick B,. Obesity: changes in lipid metabolism and the role of insulin. Clin Endocrinol Metab 1976; 5: 313-335.
38. Csiszar A, Ungvari Z,. Endothelial dysfunction and vascular inflammation in type 2 diabetes: interaction of AGE/RAGE and TNF-α signaling. Am J Physiol Heart Circ Physiol 2008; 295: H475-H476.
39. Evans JL, et al. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002; 23: 599-622.
40. Celec P,. Nuclear factor kappa B-molecular biomedicine: the next generation. Biomed Pharmacother 2004; 58: 365-371.
41. Surh YJ, et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-κ B activation. Mutat Res 2001; 480-481: 243-268.
42. Sinha S, et al. Fatty acid-induced insulin resistance in L6 myotubes is prevented by inhibition of activation and nuclear localization of nuclear factor kappa B. J Biol Chem 2004; 279: 41294-41301.